Loading...
XTAI
1733
Market cap94mUSD
Jul 09, Last price  
30.30TWD
1D
1.34%
1Q
2.89%
Jan 2017
-26.63%
IPO
50.75%
Name

Apex Biotechnology Corp

Chart & Performance

D1W1MN
XTAI:1733 chart
P/E
18.58
P/S
1.56
EPS
1.63
Div Yield, %
3.96%
Shrs. gr., 5y
-2.41%
Rev. gr., 5y
-0.61%
Revenues
1.94b
+5.00%
1,438,917,0001,749,690,0001,876,273,0002,026,086,0001,829,221,0001,788,929,0001,847,454,0001,763,284,0001,795,300,0002,043,614,0002,198,862,0002,005,337,0002,131,656,0002,244,176,0001,676,537,0001,852,211,0001,944,907,000
Net income
163m
+27.38%
326,483,000453,949,000526,617,000522,710,000371,221,000273,377,000261,853,0003,181,00085,553,00095,119,000113,859,00094,795,000202,224,000181,785,000115,783,000127,998,000163,038,000
CFO
164m
-50.06%
391,286,000465,587,000273,447,000509,665,000484,767,000267,604,000472,152,000298,057,00070,828,00067,566,000462,523,000280,603,000179,868,00026,616,000230,391,000328,669,000164,136,000
Dividend
Jun 11, 20251.2 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup features a variety of personal health monitoring systems, including those for tracking blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1c, and ketone levels. In addition, the company provides self-testing solutions for coagulation and multi-parameter analysis, alongside advanced hemoglobin screening systems. Beyond patient diagnostics, Apex Biotech also offers systems for detecting pesticide residues. The company further extends its services to include digital care management and telehealth platforms. Established in 1997, Apex Biotechnology Corp. operates from its headquarters located in Hsinchu City, Taiwan.
URL
https://www.apexbio.com.tw/
IPO date
Sep 17, 2001
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT